Aprea Therapeutics is a biotechnology business based in the US. Aprea Therapeutics shares (APRE) are listed on the NASDAQ and all prices are listed in US Dollars. Aprea Therapeutics employs 7 staff and has a trailing 12-month revenue of around $963,800.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.05 |
|---|---|
| 52-week range | $2.83 - $8.85 |
| 50-day moving average | $4.53 |
| 200-day moving average | $5.06 |
| Wall St. target price | $15.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.28 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.05 from 2024-07-23
| 1 week (2024-07-17) | 1.50% |
|---|---|
| 1 month (2024-06-24) | -2.17% |
| 3 months (2024-04-24) | -21.66% |
| 6 months (2024-01-24) | -27.94% |
| 1 year (2023-07-24) | 29.85% |
|---|---|
| 2 years (2022-07-22) | 258.41% |
| 3 years (2021-07-23) | 4.37 |
| 5 years (2019-07-20) | N/A |
| Revenue TTM | $963,800 |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -26.83% |
| Return on equity TTM | -43.83% |
| Profit margin | 0% |
| Book value | $5.33 |
| Market Capitalization | $21.7 million |
TTM: trailing 12 months
We're not expecting Aprea Therapeutics to pay a dividend over the next 12 months.
Aprea Therapeutics's shares were split on a 1:20 basis on 12 February 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aprea Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Aprea Therapeutics shares which in turn could have impacted Aprea Therapeutics's share price.
Over the last 12 months, Aprea Therapeutics's shares have ranged in value from as little as $2.83 up to $8.8465. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aprea Therapeutics's is 1.921. This would suggest that Aprea Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania. .
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.